Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Dec;71(12):3848-3856.
doi: 10.1111/jgs.18575. Epub 2023 Aug 24.

Drug-related readmissions in older hospitalized adults: External validation and updating of OPERAM DRA prediction tool

Birgitta M G Snijders  1 , Thomas G H Kempen  2   3 , Carole E Aubert  4   5 , Huiberdina L Koek  1 , Olivia Dalleur  6   7 , Jacques Donzé  4   8   9   10 , Nicolas Rodondi  4   5 , Denis O'Mahony  11   12 , Ulrika Gillespie  2   13 , Wilma Knol  1
Affiliations
Free article
Randomized Controlled Trial

Drug-related readmissions in older hospitalized adults: External validation and updating of OPERAM DRA prediction tool

Birgitta M G Snijders et al. J Am Geriatr Soc. 2023 Dec.
Free article

Abstract

Background: Drug-related readmissions (DRAs) are defined as rehospitalizations with an adverse drug event as their main or significant contributory cause. DRAs represent a major adverse health burden for older patients. A prediction model which identified older hospitalized patients at high risk of a DRA <1 year was previously developed using the OPERAM trial cohort, a European cluster randomized controlled trial including older hospitalized patients with multimorbidity and polypharmacy. This study has performed external validation and updated the prediction model consequently.

Methods: The MedBridge trial cohort (a multicenter cluster randomized crossover trial performed in Sweden) was used as a validation cohort. It consisted of 2516 hospitalized patients aged ≥65 years. Model performance was assessed by: (1) discriminative power, assessed by the C-statistic with a 95% confidence interval (CI); (2) calibration, assessed by visual examination of the calibration plot and use of the Hosmer-Lemeshow goodness-of-fit test; and (3) overall accuracy, assessed by the scaled Brier score. Several updating methods were carried out to improve model performance.

Results: In total, 2516 older patients were included in the validation cohort, of whom 582 (23.1%) experienced a DRA <1 year. In the validation cohort, the original model showed a good overall accuracy (scaled Brier score 0.03), but discrimination was moderate (C-statistic 0.62 [95% CI 0.59-0.64]), and calibration showed underestimation of risks. In the final updated model, the predictor "cirrhosis with portal hypertension" was removed and "polypharmacy" was added. This improved the model's discriminative capability to a C-statistic of 0.64 (95% CI 0.59-0.70) and enhanced calibration plots. Overall accuracy remained good.

Conclusions: The updated OPERAM DRA prediction model may be a useful tool in clinical practice to estimate the risk of DRAs in older hospitalized patients subsequent to discharge. Our efforts lay the groundwork for the future development of models with even better performance.

Keywords: drug-related readmission; external validation; older patient; prediction model.

PubMed Disclaimer

References

REFERENCES

    1. Lim R, Ellett LMK, Semple S, Roughead EE. The extent of medication-related hospital admissions in Australia: a review from 1988 to 2021. Drug Saf. 2022;45(3):249-257.
    1. El Morabet N, Uitvlugt EB, van den Bemt BJF, van den Bemt P, Janssen MJA, Karapinar-Carkit F. Prevalence and preventability of drug-related hospital readmissions: a systematic review. J Am Geriatr Soc. 2018;66(3):602-608.
    1. Blum MR, Sallevelt B, Spinewine A, et al. Optimizing therapy to prevent avoidable hospital admissions in multimorbid older adults (OPERAM): cluster randomised controlled trial. BMJ. 2021;374:n1585.
    1. Kempen TGH, Bertilsson M, Hadziosmanovic N, et al. Effects of hospital-based comprehensive medication reviews including postdischarge follow-up on older patients' use of health care: a cluster randomized clinical trial. JAMA Netw Open. 2021;4(4):e216303.
    1. O'Mahony D, Gudmundsson A, Soiza RL, et al. Prevention of adverse drug reactions in hospitalized older patients with multi-morbidity and polypharmacy: the SENATOR* randomized controlled clinical trial. Age Ageing. 2020;49(4):605-614.

Publication types